New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Subscribe To Our Newsletter & Stay Updated
